Aroa Biosurgery Ltd
Price Chart
OHLC · volume · moving averages
Market Statistics
Today's trading range
Valuation
Fundamental multiples
Trading Activity
Volume & order book
Performance
Returns across timeframes
Technical Indicators
Momentum & moving averages
— From the desk
Latest News
Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance
Aroa Biosurgery beats FY26 guidance as Myriad drives revenue 23% YoY; FY27 targets NZ$115-125m, Symphony catalyst; cash-rich, debt-free.
Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26
Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.
Aroa Biosurgery maintains cash flow momentum as Myriad Matrix product sales hit record high
Soft tissue regeneration specialist Aroa Biosurgery (ASX: ARX) has posted its second consecutive quarter of positive cash flow, in a period that also saw the company reach a key milestone with over 100 published peer reviews now validating its ECM platform in pre-clinical and clinical studies. Cash flow for the three months to end-March totalled […]
Aroa Biosurgery gains US and EU clearance for complex wound healing products
Newly-listed soft tissue regeneration company Aroa Biosurgery (ASX: ARX) has announced that its Symphony and Myriad complex wound healing products have gained clearance from international regulators. Symphony has received approval from the US Food and Drug Administration, while Myriad received European regulatory approval via CE Mark certification. Both approvals were confirmed by Aroa this morning […]